-
-
Call more information
660-596-2224 -
By Bernie Monegain Health executives know about Amazon, Apple, Google, IBM and Microsoft making moves into the healthcare industry but there are far more Fortune 50 companies that already have a foot in the space. Translation: Healthcare is even more ripe for disruption than it presently appears. And that means it’s time to act fast or face irrelevancy. […]
Read MoreAuthors: Dennis M. Fisher, M.D. et al Anesthesiology 5 2018, Vol.128, 943-952. Background: Desirable product attributes for treatment of moderate-to-severe acute pain in many medically supervised settings are rapid onset and a route of administration not requiring intravenous access. The pharmacokinetic characteristics of sublingually administered tablets containing 15 or 30 µg of sufentanil are described.Methods: Blood was sampled […]
Read MoreAuthors: Weisbord SD et al. N Engl J Med 2017 Nov 12. Saline hydration alone is sufficient. Urinary alkalinization and acetylcysteine have been proposed as possible ways to minimize contrast-induced nephropathy (CIN) in patients who receive intra-arterial injections of iodinated contrast. In this multicenter study, researchers randomized about 5000 patients scheduled for angiography (primarily coronary) to […]
Read MoreThe type of needle used during a lumbar puncture makes a significant difference in the subsequent occurrence of headache, nerve irritation, and hearing disturbance in patients, according to a study published in The Lancet. They study also found that the pencil-point atraumatic needle with the better tip design, which has been available for about 70 […]
Read MoreThe FDA approved the first once-monthly injectable buprenorphine product (Sublocade, Indivior), for the treatment of moderate to severe opioid use disorder (OUD) in adult patients who have started treatment with a transmucosal buprenorphine-containing product. It is indicated for patients who have been on a stable dose of buprenorphine treatment for a minimum of seven days. […]
Read More